Antiviral activity of molnupiravir precursor NHC against SARS-CoV-2 Variants of Concern (VOCs) and implications for the therapeutic window and resistance
T. Prince, I. Donovan-Banfield, H. Goldswain, R. Penrice-Randal, C. Hartley, T. Fletcher, S. Khoo, J. A. Hiscox
This study evaluates the antiviral activity of molnupiravir's active metabolite NHC against SARS-CoV-2 variants, finds no resistance after 20 passages, and suggests earlier administration for better efficacy.
bioRxiv · Nov 23, 2021 · PreprintMicrobiology